�ռ��ȶ��֬��ڿ��ҩ��о��չ

[1]

CHENG W W�� ALLEN T M. The use of single chain Fv as targeting agents for immunoliposomes�� an update on immunoliposomal drugs for cancer treatment[J]. Expert Opin Drug Deliv�� 2010�� 7(4)�� 461-478. [2] GUIN S�� YAO H P�� WANG M H. RON Receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxocity[J]. Mol Pharm�� 2010�� 7(2)�� 386-397. [3] CHENG W W�� ALLEN T M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma�� a comparison of whole monoclonal antibody�� Fab�� fragments and single chain Fv[J]. J Controlled Release�� 2008�� 126(1)�� 50-58. [4] HANTEL C�� LEWRICK F�� SCHNEIDER S�� et al. Anti insulin-like growth factor1 receptor immunoliposomes�� a single formulation combining two anticancer treatments with enhanced therapeutic efficiency[J]. J Clin Endocrinol Metab�� 2010�� 95(2)�� 943-952. [5] YANG T�� CHOI M K�� CUI F D�� et al. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells[J]. Pharm Res�� 2007�� 24(12)�� 2402-2411. [6] MANJAPPA A S�� CHAUDHARI K R�� VENKATARAJU M P�� et al. Antibody derivatization and conjugation strategies �� Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor[J]. J Controlled Release�� 2011��150��1��2-22. [7] FENG B�� TOMIZAWA K�� MICHIUE H�� et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His[J]. Biomaterials�� 2009�� 30(9)�� 1746-1755. [8] PAN X�� LEE R J. Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity[J]. Int J Pharm�� 2007�� 336(2)�� 276-283. [9] BARRAJON-CATALAN E�� MENENDEZ-GUTIERREZ M P�� FALCO A�� et al. Selective death of human breast cancer cells by lytic immunoliposomes�� Correlation with their HER2 expression level[J]. Cancer Lett�� 2010�� 290(2)�� 192-203. [10] RUAN W�� SASSOON A�� AN F�� et al. Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection[J]. Mol Cell Proteomics�� 2006�� 5(12)�� 2364-2373. [11] BAUM P�� MULLER D�� RUGER R�� et al. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells [J]. J Drug Target�� 2007�� 15(6)�� 399-406. [12] GOSK S�� MOOS T�� GOTTSTEIN C�� et al. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo[J]. Biochim Biophys Acta�� 2008�� 1778(4)�� 854-863. [13] MULLER D�� TRUNK G�� SICHELSTIEL A�� et al. Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice[J]. J Immunol Methods�� 2008�� 339(1)�� 90-98. [14] SAWANT R M�� COHEN M B�� TORCHILIN V P�� et al. Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro[J]. J Drug Target�� 2008�� 16(7)�� 601-604. [15] ATOBE K�� ISHIDA T�� ISHIDA E�� et al. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase(MT1-MMP)[J]. Biol Pharm Bull�� 2007�� 30(5)��972-978. [16] HATAKEYAMA H�� AKITA H�� ISHIDA E�� et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes[J]. Int J Pharm�� 2007�� 342(1-2)�� 194-200. [17] GAO J�� ZHONG W�� HE J�� et al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes[J]. Int J Pharm�� 2009�� 374(1-2)�� 145-152. [18] ROTH A�� DRUMMOND D C�� CONRAD F�� et al. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells[J]. Mol Cancer Ther�� 2007�� 6(10)�� 2737-2746. [19] HUSSAIN S�� PLUCKTHUM A�� ALLEN T M�� et al. Antitumor activity of an epithelial cell adhesion molecule-targeted nanovesicular drug delivery system[J]. Mol Cancer Ther�� 2007�� 6(11)�� 3019-3027. [20] MAMOT C�� DRUMMOND D C�� HONG K�� et al. Liposome-based approaches to overcome anticancer drug resistance[J]. Drug Resist Update�� 2003�� 6(5)�� 271-279. [21] TORCHILIN V P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging[J]. AAPS J�� 2007�� 9(2)�� 128-147. [22] GUPTA B�� TORCHILIN V P. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice[J]. Cancer Immunol Immunother�� 2007�� 56(8)�� 1215-1223. [23] NOBLE C O�� GUO Z�� HAYES M E�� et al. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine[J]. Cancer Chemother Pharmacol�� 2009�� 64(4)�� 741-751. [24] MINKO T�� PAKUNLU R I�� WANG Y�� et al. New generation of liposomal drugs for cancer[J]. Anticancer Agents Med Chem�� 2006�� 6(6)�� 537-552. [25] PASTORINO F�� BRIGNOLE C�� DI PAOLO D�� et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy[J]. Cancer Res�� 2006�� 66(20)�� 10073-10082. [26] ROTH P�� HAMMER C�� PIGUET A C�� et al. Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2[J]. J Drug Target�� 2007�� 15(9)�� 623-631. [27] KIM M J�� LEE H J�� LEE I A�� et al. Preparation of pH-sensitive�� long-circulating and EGFR-targeted immunoliposomes[J]. Arch Pharm Res�� 2008�� 31(4)�� 539-546. [28] KIM I Y�� KANG Y S�� LEE D S�� et al. Antitumor activity of EGFR targeted PH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice[J]. J Controlled Release�� 2009�� 140(1)�� 55-60. [29] SIMARD P�� LEROUX J C. pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells[J]. Int J Pharm�� 2009�� 381(2)�� 86-96. [30] PARK J W�� BENZ C C�� MARTIN F J. Future directions of liposome- and immunoliposome-based cancer therapeutics[J]. Semin Oncol�� 2004�� 31(6)�� 196-205.